



## EBOS ASX LISTING CONFIRMED

News release

4 December 2013

---

EBOS is pleased to confirm that the Company's application to list on the ASX has been approved.

ASX has reserved 6 December 2013 as the listing date and trading is expected to commence on or around that date under the code EBO. The Company's primary listing will remain on the NZX.

EBOS Managing Director Mark Waller says the dual listing on the ASX will facilitate the ability of Australian institutional and retail investors to trade the Company's shares, deepening liquidity for the benefit of all shareholders.

"The \$1.1 billion acquisition of Symbion earlier this year transformed EBOS into the largest diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products by revenue and a leading Australasian animal care products marketer, wholesaler and distributor. Since this acquisition we have received increasing interest from Australian investors who want to participate in the EBOS growth story."

EBOS gained further recognition for its determination to be the leading player in the markets in which it operates with the accolade of the "Best Growth Strategy" in the Deloitte Top 200 Awards announced last week.

"EBOS is delighted to receive recognition for its strategy which continues to deliver exceptional performance for our shareholders amounting to compounding returns of 19 per cent over the last 10 years," says Mr Waller.

Ends

Authorised for release

Dennis Doherty

CFO

EBOS GROUP Limited

DDI 03 339 5062